Abstract:Following the publication of this article, an interested reader drew to the authors' attention that the flow cytometric (FCM) plots in Fig. 2A on p. 2278 showing the 'Dasatinib' and 'CA‐4' experiments were duplicates of each other. After having re‐examined their original data, and due to the overall similarity of the data, the authors have realized that these data were inadvertently assembled incorrectly in the figure. They realize that they also made a further mistake regarding the writing of the ratios of mitochondrial membrane‐depolarized HO‐8910 cells for these FCM plots (essentially, these were written the wrong way around): The percentage of mitochondrial membrane‐depolarized HO‐8910 cells should have been written as 22.50% for the dasatinib‐treated cells (the centre‐left FCM plot) and 15.71% for the CA‐4‐treated cells (centre‐right plot). A revised version of Fig. 2 now showing alternative data for the FCM experiments shown in Fig. 2A, is shown on the next page. Note that the errors made in terms of assembling the data in Fig. 2A did not greatly affect either the results or the conclusions reported in this paper, and all the authors agree with the publication of this corrigendum. The authors regret that these errors went unnoticed prior to the publication of their article, and are grateful to the Editor of Oncology Reports for granting them this opportunity to publish a corrigendum. Furthermore, they apologize to the readership for any inconvenience caused. [Oncology Reports 29: 2275‐2282, 2013; DOI: 10.3892/or.2013.2405]

Correction to: Cypripedin, a phenanthrenequinone from Dendrobium densiflorum, sensitizes non-small cell lung cancer H460 cells to cisplatin-mediated apoptosis

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Author Correction: Synergistic Suppression of Human Breast Cancer Cells by Combination of Plumbagin and Zoledronic Acid in Vitro

Correction: Pomegranate extract-loaded sphingosomes for the treatment of cancer: Phytochemical investigations, formulation, and antitumor activity evaluation

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Correction: Xiang, S., Et Al. Schisandrin B Induces Apoptosis and Cell Cycle Arrest of Gallbladder Cancer Cells. Molecules 2014, 19, 13235–13250

Correction: Corrigendum: Patient-specific Hepatocyte-Like Cells Derived from Induced Pluripotent Stem Cells Model Pazopanib-Mediated Hepatotoxicity

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Correction to: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo

Erratum: Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells.

Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors Via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

Correction: Corrigendum: Inhibitory Receptors Bind ANGPTLs and Support Blood Stem Cells and Leukaemia Development

[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‐4 in vitro and in vivo

Plumbagin Attenuates Cancer Cell Growth and Osteoclast Formation in the Bone Microenvironment of Mice